Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype
Modern Pathology · 2024
DOI: 10.1016/j.modpat.2024.100530 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Pathology, 2024. Verfasst von Rana Ajabnoor und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Rochester Medical Center, Rochester, New York; Department of Pathology, Faculty of Medicine, King Abdulaziz Un…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immunohistochemistry, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: AstraZeneca, Agendia, Gilead Sciences.
Abstract (Originalsprache)
Breast cancer (BC) with average human epidermal growth factor receptor 2 (HER2) signals/cell ≥6 and HER2/chromosome enumeration probe 17 (CEP17) ratio
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Rochester Medical Center, Rochester, New York; Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
- Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
- Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
- Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia.
- Department of Pathology, University of Rochester Medical Center, Rochester, New York.
- Department of Medicine, University of Rochester Medical Center, Rochester, New York.
Förderung
- AstraZeneca
- Agendia
- Gilead Sciences
Zitieren
APA
Ajabnoor, R., Zhang, G., Hu, Y., Gao, Y., Finkelman, B. S., Turner, B. M., Yi, S., Dhakal, A., Audeh, W., Li, Z., Li, X., Hicks, D. G., & Zhang, H. (2024). Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100530
Vancouver
Ajabnoor R, Zhang G, Hu Y, Gao Y, Finkelman BS, Turner BM, et al. Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100530
BibTeX
@article{Ajabnoor2024,
author = {Ajabnoor, Rana and Zhang, Gloria and Hu, Yan and Gao, Yuan and Finkelman, Brian S and Turner, Bradley M and Yi, Sha and Dhakal, Ajay and Audeh, William and Li, Zaibo and Li, Xiaoxian and Hicks, David G and Zhang, Huina},
title = {Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype},
journal = {Modern Pathology},
year = {2024},
doi = {10.1016/j.modpat.2024.100530}
}
EUVIMED